Celltrion has been focusing on the development of corona19 therapeutic antibodies based on existing influenza multi-antibody new drugs and experience in developing antibodies for the treatment of MERS (Middle East Respiratory Syndrome). Currently, company-wide researchers are working on developing a 24-hour treatment.Celltrion said, “We plan to put all our capabilities into the development of therapeutics by completing the establishment of a collaborative system with the Centers for Disease Control and Prevention.” |